METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
Clinical trials for METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cancer drug trial pulled before it even started
Disease control TerminatedThis was a planned early-stage trial to test a new oral drug called ERW316, alone or with hormone therapies, in people with advanced breast cancer or other solid tumors. The study aimed to find a safe dose and check for side effects. However, the trial was withdrawn before any pa…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New study checks kidney impact on prostate cancer drug safety
Disease control OngoingThis study looks at how well the body handles a radioactive drug (lutetium vipivotide tetraxetan) in men with advanced prostate cancer that has spread and no longer responds to hormone therapy. Researchers want to see if different levels of kidney function change how the drug spr…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Cancer drug safety tracked in ongoing rollover trial
Disease control ENROLLING_BY_INVITATIONThis study monitors long-term safety in 120 cancer patients who are already benefiting from treatments like JNJ-75348780, safimaltib, or ibrutinib in earlier trials. Participants have blood cancers, solid tumors, or prostate cancer. The goal is to track serious side effects over …
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Extended immunotherapy shows promise for tough prostate cancer
Disease control OngoingThis early-phase trial is testing whether giving an extra dose of the immunotherapy drug Sipuleucel-T can strengthen the immune system's attack on prostate cancer that has spread and stopped responding to hormone therapy. Fifteen men with this advanced cancer will receive three i…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New combo therapy aims to control advanced prostate cancer
Disease control OngoingThis study tests whether adding a hormone therapy to a targeted radiation drug (lutetium-177) is safe and effective for men with a certain type of advanced prostate cancer that has spread and stopped responding to hormone therapy alone. About 7 participants will receive either th…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New radioactive therapy could delay chemotherapy for prostate cancer
Disease control OngoingThis phase 2 study tests a radioactive drug called Lu-PSMA-617 against standard hormone therapy in 63 Chinese men with advanced prostate cancer that has stopped responding to treatment. The drug targets cancer cells with radiation. The goal is to see if it can delay cancer growth…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for Hard-to-Treat cancers: NUV-1511 enters human trials
Disease control OngoingThis study tests a new drug, NUV-1511, in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the drug can shrink tumors in cancers like breast, prostate, pancreatic, and ovarian cancer. About 466 adults will ta…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC